Appropriate Treatment Approaches in Patients Through Every Stage of Hodgkin Lymphoma


Individualized Treatment Approaches in Patients with Newly Diagnosed Hodgkin Lymphoma
Alison J. Moskowitz, MD

With treatment regimens in Hodgkin lymphoma expanding, clinicians must be aware of these options, including the limitations and benefits of each approach. In this activity, Dr. Sarah Rutherford discusses CD30-directed therapy in newly diagnosed HL, relapsed/refractory HL, and the clinical trials anticipated to change clinical practice.

Begin


Advanced-stage cHL: Rethinking Our Options in Frontline Therapy
Jonathon B. Cohen, MD, MS

New strategies are emerging to improve the frontline treatment of patients with newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL). In this interview, Dr. Jonathon Cohen discusses results from recent clinical trials that are making an impact on the frontline management of advanced-stage cHL. He also outlines how these advances will influence clinical practice and positively impact current standards of care for the disease.

Begin


The Treatment of R/R cHL in the Era of Checkpoint Inhibitors
Catherine Diefenbach, MD

The treatment landscape for relapsed/refractory classical Hodgkin lymphoma (R/R cHL) is expanding thanks to the development of immunotherapies like checkpoint inhibitors. In this activity, Dr. Catherine Diefenbach summarizes current salvage treatment options for R/R cHL—including their benefits and risks—and discusses the efficacy and safety of immunotherapy in the management of this difficult-to-treat patient population.

Begin


Treating Advanced HL in 2019
Sarah Rutherford, MD

With treatment regimens in Hodgkin lymphoma expanding, clinicians must be aware of these options, including the limitations and benefits of each approach. In this activity, Dr. Sarah Rutherford discusses CD30-directed therapy in newly diagnosed HL, relapsed/refractory HL, and the clinical trials anticipated to change clinical practice.

Begin

MediCom Worldwide, Inc. would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support. To better serve the needs of our audience, ManagingHodgkinLymphoma.com is now ManagingLymphoma.com

©2019 MediCom Worldwide, Inc. All rights reserved